GSK outlines multi-site plan for new US COPD med Trelegy Ellipta

By Gareth Macdonald

- Last updated on GMT

Related tags Asthma

GSK API manufacturing site in Singapore (Source GSK website)
GSK API manufacturing site in Singapore (Source GSK website)
The APIs for the newly US approved three-in-one COPD drug Trelegy Ellipta will be made at facility in Singapore according to GSK.

GSK announced the approval in a London Stock Exchange (LSE) filing yesterday, telling investors Trelegy Ellipta is first once-daily product approved in the US that combines three active molecules in a single inhaler.

The announcement came days after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP​) recommended the product be approved for moderate to severe chronic obstructive pulmonary disease (COPD).

The active pharmaceutical ingredients (APIs) in Trelegy Ellipta are: the corticosteroid fluticasone furoate; the long-acting muscarinic antagonist umeclidinium; and the long-acting beta2-adrenergic agonist vilanterol.

All three ingredients are produced at GSK’s plant in Jurong, Singapore.

Delivery device

The actives are delivered using the Ellipta drug powder inhaler, which was developed by US-based Innoviva Inc. The technology is used in a number of products in GSK’s respiratory disease franchise, including Anoro, Incruse and Revlar.

The finished Trelegy Ellipta inhalers are produced at GSK’s facility in Ware, Hertfordshire in the UK according to Anna Gibbins, head of communications for GSK’s respiratory franchise.

In July​ last year, GSK said it would spend £74m ($99m) at the site to increase Ellipta production capacity.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more